GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (FRA:1K9) » Definitions » COGS-to-Revenue

CareDx (FRA:1K9) COGS-to-Revenue : 0.36 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is CareDx COGS-to-Revenue?

CareDx's Cost of Goods Sold for the three months ended in Mar. 2024 was €23.9 Mil. Its Revenue for the three months ended in Mar. 2024 was €66.3 Mil.

CareDx's COGS to Revenue for the three months ended in Mar. 2024 was 0.36.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CareDx's Gross Margin % for the three months ended in Mar. 2024 was 64.01%.


CareDx COGS-to-Revenue Historical Data

The historical data trend for CareDx's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CareDx COGS-to-Revenue Chart

CareDx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.33 0.33 0.35 0.36

CareDx Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.37 0.37 0.39 0.36

CareDx COGS-to-Revenue Calculation

CareDx's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=93.533 / 257.057
=0.36

CareDx's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=23.859 / 66.285
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CareDx  (FRA:1K9) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CareDx's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 23.859 / 66.285
=64.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


CareDx COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CareDx's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CareDx (FRA:1K9) Business Description

Traded in Other Exchanges
Address
8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia and Stockholm, Sweden.

CareDx (FRA:1K9) Headlines

No Headlines